Yes / Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active in the tumor environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer drug discovery. In this study we evaluated in silico docking to develop MMP-subtype-selective tumor-activated prodrugs. Proof of principle for this therapeutic approach was demonstrated in vitro against an aggressive human glioma model, with involvement of MMPs confirmed using pharmacological inhibition.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/12041 |
| Date | 04 May 2017 |
| Creators | Jain, M., Harburn, J.J., Gill, Jason H., Loadman, Paul, Falconer, Robert A., Mooney, C.A., Cobb, S.L., Berry, David J. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Accepted manuscript |
| Rights | (c) 2017 ACS. This document is the Accepted Manuscript version of a Published Work that appeared in final form in the Journal of Medicinal Chemistry. To access the final edited and published work see http://dx.doi.org/10.1021/acs.jmedchem.6b01472., Unspecified |
Page generated in 0.002 seconds